EDESA BIOTECH, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
EDESA BIOTECH, INC. (EDSA) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $547.46 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-13
- EDESA BIOTECH, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $547.46K, a 208.64% increase year-over-year.
- EDESA BIOTECH, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $484.85K, a 627.43% increase year-over-year.
- EDESA BIOTECH, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $399.86K, a 392.54% increase year-over-year.
- EDESA BIOTECH, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $404.43K, a 330.55% increase year-over-year.
- EDESA BIOTECH, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $729.64K, a 35.75% increase from fiscal 2024.
- EDESA BIOTECH, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $537.49K, a 56.88% decline from fiscal 2023.
- EDESA BIOTECH, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $1.25M.
- EDESA BIOTECH, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2018 was $154.31K, a 33.55% increase from fiscal 2017.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 1 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $547.46K 10-Q · filed 2026-08-13 | $1.03M derived: sum of 2 quarters · filed 2026-08-13 | $1.43M 10-Q · filed 2026-08-13 | $1.84M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | $484.85K 10-Q · filed 2026-05-14 | $884.72K 10-Q · filed 2026-05-14 | $1.29M derived: sum of 3 quarters · filed 2026-05-14 | $1.47M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-12-31 | $399.86K 10-Q · filed 2026-02-13 | $804.29K derived: sum of 2 quarters · filed 2026-02-13 | $981.67K derived: sum of 3 quarters · filed 2026-08-13 | $1.05M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-09-30 | $404.43K derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-12 | $581.81K derived: sum of 2 quarters · filed 2026-08-13 | $648.46K derived: sum of 3 quarters · filed 2026-08-13 | $729.64K 10-K · filed 2025-12-12 | |
| 2025-06-30 | $177.38K 10-Q · filed 2026-08-13 | $244.03K derived: sum of 2 quarters · filed 2026-08-13 | $325.22K 10-Q · filed 2026-08-13 | $419.15K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | $66.65K 10-Q · filed 2026-05-14 | $147.84K 10-Q · filed 2026-05-14 | $241.77K derived: sum of 3 quarters · filed 2026-05-14 | $351.27K derived: sum of 4 quarters · filed 2026-05-14 | |
| 2024-12-31 | $81.18K 10-Q · filed 2026-02-13 | $175.12K derived: sum of 2 quarters · filed 2026-02-13 | $284.62K derived: sum of 3 quarters · filed 2026-02-13 | $434.32K derived: sum of 4 quarters · filed 2026-02-13 | |
| 2024-09-30 | $93.93K derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-12 | $203.44K derived: sum of 2 quarters · filed 2025-12-12 | $353.13K derived: sum of 3 quarters · filed 2025-12-12 | $537.49K 10-K · filed 2025-12-12 | |
| 2024-06-30 | $109.51K 10-Q · filed 2025-08-08 | $259.20K derived: sum of 2 quarters · filed 2025-08-08 | $443.56K 10-Q · filed 2025-08-08 | $960.64K derived: sum of 4 quarters · filed 2025-08-08 | |
| 2024-03-31 | $149.70K 10-Q · filed 2025-05-14 | $334.05K 10-Q · filed 2025-05-14 | $851.13K derived: sum of 3 quarters · filed 2025-05-14 | $959.29K derived: sum of 4 quarters · filed 2025-05-14 | |
| 2023-12-31 | $184.36K 10-Q · filed 2025-02-14 | $701.43K derived: sum of 2 quarters · filed 2025-02-14 | $809.59K derived: sum of 3 quarters · filed 2025-02-14 | ||
| 2023-09-30 | $517.08K derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-13 | $625.24K derived: sum of 2 quarters · filed 2024-12-13 | $1.25M 10-K · filed 2024-12-13 | ||
| 2023-06-30 | $108.16K 10-Q · filed 2024-08-09 | $729.38K 10-Q · filed 2024-08-09 | |||
| 2019-03-31 | $18.16K 10-Q · filed 2019-05-08 | $45.20K 10-Q · filed 2019-05-08 | |||
| 2018-09-30 | $154.31K 10-K · filed 2018-11-30 | ||||
| 2018-03-31 | $73.46K 10-Q · filed 2019-05-08 | $94.17K 10-Q · filed 2019-05-08 | |||
| 2017-09-30 | $115.55K 10-K · filed 2018-11-30 | ||||
| 2016-09-30 | $49.60K derived: 10-K 12 month − 10-Q 9 month · filed 2017-12-01 | $92.05K derived: sum of 2 quarters · filed 2017-12-01 | $134.88K derived: sum of 3 quarters · filed 2017-12-01 | $259.38K 10-K · filed 2017-12-01 | |
| 2016-06-30 | $42.45K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-08-09 | $85.28K derived: sum of 2 quarters · filed 2016-08-09 | $209.78K 10-Q · filed 2016-08-09 | $232.22K derived: sum of 4 quarters · filed 2017-12-01 | |
| 2016-03-31 | $42.83K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-05-09 | $167.33K 10-Q · filed 2016-05-09 | $189.77K derived: sum of 3 quarters · filed 2017-12-01 | $235.62K derived: sum of 4 quarters · filed 2017-12-01 | |
| 2015-12-31 | $124.50K 10-Q · filed 2016-02-08 | $146.94K derived: sum of 2 quarters · filed 2017-12-01 | $192.79K derived: sum of 3 quarters · filed 2017-12-01 | $304.85K derived: sum of 4 quarters · filed 2017-12-01 | |
| 2015-09-30 | $22.44K derived: 10-K 12 month − 10-Q 9 month · filed 2017-12-01 | $68.30K derived: sum of 2 quarters · filed 2017-12-01 | $180.36K derived: sum of 3 quarters · filed 2017-12-01 | $267.22K 10-K · filed 2017-12-01 | |
| 2015-06-30 | $45.85K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-08-09 | $157.92K derived: sum of 2 quarters · filed 2016-08-09 | $244.78K 10-Q · filed 2016-08-09 | ||
| 2015-03-31 | $112.06K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-05-09 | $198.93K 10-Q · filed 2016-05-09 | |||
| 2014-12-31 | $86.86K 10-Q · filed 2016-02-08 | ||||
| 2014-09-30 | $36.51K 10-K · filed 2016-12-14 | ||||
| 2014-08-31 | $956.63K 10-K · filed 2016-12-14 | ||||
| 2014-06-30 | $156.47K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-08-10 | $302.06K derived: sum of 2 quarters · filed 2015-08-10 | $770.78K 10-Q · filed 2015-08-10 | ||
| 2014-03-31 | $145.59K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-05-11 | $614.31K 10-Q · filed 2015-05-11 | |||
| 2013-12-31 | $468.72K 10-Q · filed 2015-02-09 | ||||
| 2013-09-30 | $77.74K 10-Q · filed 2015-02-09 | ||||
| 2013-08-31 | $786.59K 10-K · filed 2015-12-14 | ||||
| 2012-08-31 | $714.20K 10-K · filed 2014-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B |